Gilead's Head Of Commercial Operations To Step Down

Published: Jan 08, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc said on Monday that its head of commercial operations for the past decade, Kevin Young, who oversaw tremendous sales growth at the U.S. biotechnology company, will retire next month. Young, who plans to step down on February 4, has held the top commercial post for the world's leading maker of HIV/AIDS medicines since 2004. During his tenure Gilead's annual sales grew from $1.24 billion in 2004 to about $11 billion in 2013. "Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas," Gilead Chief Executive John Martin said in a statement.

Help employers find you! Check out all the jobs and post your resume.

Back to news